HomeCompareNMRD vs JNJ

NMRD vs JNJ: Dividend Comparison 2026

NMRD yields 1000000.00% · JNJ yields 2.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NMRD wins by $4.7683925249533696e+36M in total portfolio value
10 years
NMRD
NMRD
● Live price
1000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.7683925249533696e+36M
Annual income
$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00
Full NMRD calculator →
JNJ
Johnson & Johnson
● Live price
2.14%
Share price
$242.49
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.5K
Annual income
$4,749.88
Full JNJ calculator →

Portfolio growth — NMRD vs JNJ

📍 NMRD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNMRDJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NMRD + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NMRD pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NMRD
Annual income on $10K today (after 15% tax)
$85,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$182.28/yr
After 10yr DRIP, annual income (after tax)
$4,037.40/yr
At 15% tax rate, NMRD beats the other by $4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NMRD + JNJ for your $10,000?

NMRD: 50%JNJ: 50%
100% JNJ50/50100% NMRD
Portfolio after 10yr
$2.3841962624766848e+36M
Annual income
$2,383,727,347,228,033,600,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.98%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

NMRD
Analyst Ratings
2
Buy
Consensus: Buy
Altman Z
-23.5
Piotroski
1/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-5.7% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NMRD buys
0
JNJ buys
0
PoliticianChamberTickerTypeAmountDate
Dianne Feinstein🏛 Senate$NMRD▼ Sell$15,001 - $50,0002022-01-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNMRDJNJ
Forward yield1000000.00%2.14%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$4.7683925249533696e+36M$30.5K
Annual income after 10y$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00$4,749.88
Total dividends collected$4.7683311610149396e+36M$15.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: NMRD vs JNJ ($10,000, DRIP)

YearNMRD PortfolioNMRD Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$100,010,700$100,000,000.00$10,594$274.49+$100.00MNMRD
2$934,786,450,701$934,679,439,252.34$11,294$360.69+$934786.44MNMRD
3$8,165,787,108,578,292$8,164,786,887,076,042.00$12,133$476.91+$8165787108.57MNMRD
4$66,665,884,190,957,650,000$66,657,146,798,751,470,000.00$13,156$635.42+$66665884190957.63MNMRD
5$508,662,171,058,048,100,000,000$508,590,838,561,963,700,000,000.00$14,432$854.61+$508662171058048128.00MNMRD
6$3,627,235,248,428,489,700,000,000,000$3,626,690,979,905,457,600,000,000,000.00$16,056$1,162.76+$3.62723524842849e+21MNMRD
7$24,173,681,159,150,610,000,000,000,000,000$24,169,800,017,434,790,000,000,000,000,000.00$18,175$1,604.53+$2.417368115915061e+25MNMRD
8$150,567,402,861,454,640,000,000,000,000,000,000$150,541,537,022,614,370,000,000,000,000,000,000.00$21,009$2,252.68+$1.5056740286145463e+29MNMRD
9$876,477,100,281,847,600,000,000,000,000,000,000,000$876,315,993,160,785,800,000,000,000,000,000,000,000.00$24,911$3,229.73+$8.764771002818475e+32MNMRD
10$4,768,392,524,953,369,600,000,000,000,000,000,000,000,000$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00$30,458$4,749.88+$4.7683925249533696e+36MNMRD

NMRD vs JNJ: Complete Analysis 2026

NMRDStock

Nemaura Medical Inc., a medical technology company, discovers, develops, and commercializes diagnostic medical devices. It provides sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.

Full NMRD Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this NMRD vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NMRD vs SCHDNMRD vs JEPINMRD vs ONMRD vs KONMRD vs MAINNMRD vs ABBVNMRD vs MRKNMRD vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.